Portal de Periódicos da CAPES

Emerging Resistance to Fluoroquinolones in Staphylococci: An Alert

1991; American College of Physicians; Volume: 114; Issue: 5 Linguagem: Inglês

10.7326/0003-4819-114-5-424

1539-3704

Michele Trucksis, David C. Hooper, J S Wolfson,

Bacterial Identification and Susceptibility Testing

Editorials1 March 1991Emerging Resistance to Fluoroquinolones in Staphylococci: An AlertMichele Trucksis, PhD, MD, David C. Hooper, MD, John S. Wolfson, MD, PhDMichele Trucksis, PhD, MD, David C. Hooper, MD, John S. Wolfson, MD, PhDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-5-424 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe fluoroquinolones are orally administered antimicrobial agents introduced in the mid-1980s. Although they are particularly effective for treating gram-negative bacillary infections, some agents, including ciprofloxacin, ofloxacin, and pefloxacin, are also active against gram-positive organisms. These agents have shown promise as alternatives to parenteral vancomycin for treating infections with methicillin-resistant Staphylococcus aureus. With fluoroquinolone use, however, therapeutic failures associated with isolation of fluoroquinolone-resistant strains of staphylococci are being increasingly documented. We discuss the use of fluoroquinolones as therapeutic agents for staphylococcal infections, problems with bacterial resistance, and approaches to suppression of resistance.Staphylococci have long been important causes of both community-...References1. HoranCulverJarvis TDW. Pathogens causing nosocomial infections: preliminary data from the national nosocomial infections surveillance system. Antimicrobic Newsletter. 1988;5:65-7. CrossrefGoogle Scholar2. BarryJones AR. In vitro activity of ciprofloxacin against gram-positive cocci. Am J Med. 1987;82(Suppl 4A):27-32. MedlineGoogle Scholar3. Mitsuhashi S. Comparative antibacterial activity of new quinolone-carboxylic acid derivatives. Rev Infect Dis. 1988;10(Suppl. 1):S27-31. CrossrefMedlineGoogle Scholar4. EspinozaChinNovelliNeu ANAH. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob Agents Chemother. 1988;32:663-70. CrossrefMedlineGoogle Scholar5. JonesBarry RA. In vitro evaluation of WIN 57273, a new broad-spectrum fluoroquinolone. Antimicrob Agents Chemother. 1990;34:306-13. CrossrefMedlineGoogle Scholar6. SmithEng SR. Activity of ciprofloxacin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1985;27:688-91. CrossrefMedlineGoogle Scholar7. SandeBrooks-FournierGerberding MRJ. Use of animal models in evaluation of the quinolones. Rev Infect Dis. 1988;10(Suppl. 1):S113-6. CrossrefMedlineGoogle Scholar8. KaatzSeoBarriereAlbrechtRybak GSSLM. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1990;34:257-60. CrossrefMedlineGoogle Scholar9. DesplacesAcar NJ. New quinolones in the treatment of bone and joint infections. Rev Infect Dis. 1988;10(Suppl. 1):S179-83. CrossrefMedlineGoogle Scholar10. PiercyBarbaroLubyMackowiak EDJP. Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 1989;33:128-30. CrossrefMedlineGoogle Scholar11. Righter J. Ciprofloxacin treatment of Staphylococcus aureus infections. J Antimicrob Chemother. 1987;20:595-7. CrossrefMedlineGoogle Scholar12. HumphreysMulvhill HE. Ciprofloxacin-resistant Staphylococcus aureus [Letter]. Lancet. 1985;2:383. CrossrefMedlineGoogle Scholar13. FrenchLingLingHui GJTY. Susceptibility of Hong Kong isolates of methicillin-resistant Staphylococcus aureus to antimicrobial agents. J Antimicrob Chemother. 1988;21:581-8. CrossrefMedlineGoogle Scholar14. Schaefler S. Methicillin-resistant strains of Staphylococcus aureus resistant to quinolones. J Clin Microbiol. 1989;27:335-6. CrossrefMedlineGoogle Scholar15. WolffBurePathe MAJ. Evolution des résistances bactériennes à la péfloxacine dans le service de réanimation de l'hôpital Claude Bernard. In: Pocidalo JJ, Vachon F, Régnier B, eds. Les Nouvelles Quinolones. Paris: Editions Arnette; 1985:213-25. Google Scholar16. StrausbaughJacobsonSewellWard LCDT. Emergence of ciprofloxacin (Cip) resistance during an outbreak caused by methicillin-resistant Staphylococcus aureus (MRSA) in a nursing home care unit (NHCU) [Abstract no. 1257]. Program Abstracts 29th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1989. Google Scholar17. OppenheimHartleyLeeBurnie BJWJ. Outbreak of coagulase negative staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. BMJ. 1989;299:294-7. CrossrefMedlineGoogle Scholar18. KotilainenNikoskelainenHuovinen PJP. Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin. J Infect Dis. 1990;161:41-4. CrossrefMedlineGoogle Scholar19. ShalitBergerGoreaFrimerman ISAH. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989;33:593-4. CrossrefMedlineGoogle Scholar20. WolfsonHooper JD. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev. 1989;2:378-424. CrossrefMedlineGoogle Scholar21. YoshidaBogakiNakamuraUbukataKonno HMSKM. Nucleotide sequence and characterization of the Staphylococcus aureus nor A gene, which confers resistance to quinolones. J Bacteriol. 1990;172:6942-9. CrossrefMedlineGoogle Scholar22. SreedharanOramJensenPetersonFisher SMBLL. DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli. J Bacteriol. 1990;172:7260-2. CrossrefMedlineGoogle Scholar23. RohnerHerterAuckenthalerPechèreWaldvogelLew PCRJFD. Synergistic effect of quinolones and oxacillin on methicillin-resistant Staphylococcus species. Antimicrob Agents Chemother. 1989;33:2037-41. CrossrefMedlineGoogle Scholar24. KaatzSeoBarriereAlbrechtRybak GSSLM. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1989;33:1184-7. CrossrefMedlineGoogle Scholar25. DworkinSandeLeeChambers RMBH. Treatment of rightsided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin. Lancet. 1989;2:1071-3. CrossrefMedlineGoogle Scholar26. DesplacesGutmannCarletGuibertAcar NLJJJ. The new quinolones and their combinations with other agents for therapy of severe infections. J Antimicrob Chemother. 1986;17:25-39. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Massachusetts General Hospital Harvard Medical School Boston, MA 02114-2696 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOpportunities to Improve Fluoroquinolone Prescribing in the United States for Adult Ambulatory Care VisitsAntimicrobial Prophylaxis in HematologyQuinolonesAntibacterial activities of nemonoxacin against clinical isolates of Staphylococcus aureus: an in vitro comparison with three fluoroquinolonesTreatment of Experimental and Human Bacterial Endocarditis with Quinolone Antimicrobial AgentsHigh expression of a plectasin-derived peptide NZ2114 in Pichia pastoris and its pharmacodynamics, postantibiotic and synergy against Staphylococcus aureusCiprofloxacinSurmounting antimicrobial resistance in the Millennium Superbug: Staphylococcus aureusGender Differences in Emerging Infectious DiseasesQuinolonesBarrier precautions, prophylaxis and neutropenic feverThe Use of Daptomycin for Staphylococcus Aureus Infections in Critical Care MedicineAntibacterial prophylaxis in neutropenic patientsUse of daptomycin for treatment of Staphylococcus aureus infectionsQuinolone Resistant Staphylococcus aureus in Okigwe, Imo State NigeriaInjuries from Nonvenomous Aquatic AnimalsMolecular Characterization of 8-Methoxyfluoroquinolone Resistance in a Clinical Isolate of Methicillin-Resistant Staphylococcus aureusStaphylococcal Skin Infections in ChildrenTratamento e prevenção das infecções e da colonização por Staphylococcus aureusMechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin in Staphylococcus aureusBacteremia Due to Quinolone‐Resistant Escherichia coli in a Teaching Hospital in South KoreaMechanisms Responsible for Cross-Resistance and Dichotomous Resistance among the QuinolonesInduction of Fibronectin-Binding Proteins and Increased Adhesion of Quinolone-Resistant Staphylococcus aureus by Subinhibitory Levels of CiprofloxacinEpidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compoundsExamination of Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus Mutants with Low-Level Fluoroquinolone ResistanceRESISTANCE ISSUES AND TREATMENT IMPLICATIONS: PNEUMOCOCCUS, STAPHYLOCOCCUS AUREUS, AND GRAM-NEGATIVE RODSStaphylococcus aureus InfectionsApplication of the ATC/DDD methodology to monitor antibiotic drug useAminoglycosides, Vancomycin, and QuinolonesQuinolone susceptibility of norA-disrupted Staphylococcus aureusActive efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniaeManagement of osteomyelitisIncreased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacinQuinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureusNorA plasmid resistance to fluoroquinolones: role of copy number and norA frameshift mutationsResistance to fluoroquinolones in Escherichia coli isolated from poultryInfection After Lung TransplantationIn vitro evaluation of DV-7751a, a new fluoroquinolone with an enhanced spectrum of activity against gram-positive aerobic organisms and anaerobesEfficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infectionsFeasibility of outpatient management of fever in cancer patients with low-risk neutropenia: Results of a prospective randomized trialChemoprophylaxis for the prevention of bacterial and fungal infectionsEvolution of bacterial susceptibility to antibiotics during a six-year period in a haematology unitQuinolonesUpdate of lomefloxacin in vitro activity and spectrumAcute bacterial diarrhoea in the emergency room: therapeutic implications of stool culture results.Trends in bacterial infections in febrile neutropenic patients: 1986-1992Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drug addicts with infective endocarditisPrinciples of Antibiotic TherapyEmergence of fluoroquinolone-resistant Escherichia coli at a cancer centerIn vitro elution of ciprofloxacin from polymethylmethacrylate cement beadsManagement of Infections in Leukemia and LymphomaIntravenous Ciprofloxacin Versus Imipenem/ Cilastatin in the Treatment of Severe PneumoniaPlace des nouvelles molécules en antibioprophylaxie chirurgicaleThe Appropriateness of Oral Fluoroquinolone-Prescribing in the Long-Term Care SettingInfluence of rifampin on fleroxacin pharmacokineticsPharmacokinetics and serum bactericidal titers of ciprofloxacin and ofloxacin following multiple oral doses in healthy volunteersGyrA sequence analysis of Staphylococcus aureus and methicillin-resistant S. aureus strains selected, in vitro, for high-level ciprofloxacin resistanceANTIMICROBIAL AGENTS IN URINARY TRACT INFECTIONS IN PATIENTS WITH SPINAL CORD INJURYEvolving Risk Factors for Infectious Complications of Cancer TherapyThe Antimicrobial ArmamentariumManagement of Fever in Patients with Cancer and Treatment-Induced NeutropeniaSupportive therapy in management of leukemiasIntravenous Ciprofloxacin: A Position Statement by the Society of Infectious Diseases PharmacistsThe new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patientsMethicillin-Resistant Staphylococcus aureus: A Questionnaire Survey of 75 Long-Term Care Facilities in Western New YorkMethicillin-resistant Staphylococcus Aureus InfectionOfloxacin, a new broad-spectrum fluoroquinolone results from a multicenter, national comparative activity surveillance studyEvaluation of new quinolonesThe fluoroquinolones: Clinical and laboratory considerationsIntravenous Ciprofloxacin Therapy in Respiratory InfectionsIn vitro activity of temafloxacin against gram-positive cocci including methicillin-resistant Staphylococcus aureusSystemic management of cutaneous bacterial infectionsThe FluoroquinolonesOral Quinolone Treatment for OsteomyelitisHenry M. Blumberg, MDThe child with cancer and infection. I. Empiric therapy for fever and neutropenia, and preventive strategiesEfficacies of various antimicrobial agents in treatment of Staphylococcus aureus abscesses and correlation with in vitro tests of antimicrobial activity and neutrophil killingA novel locus conferring fluoroquinolone resistance in Staphylococcus aureusOral Antimicrobial Therapy for OsteomyelitisLayne O. Gentry, MD 1 March 1991Volume 114, Issue 5Page: 424-426KeywordsAntimicrobial resistanceAntimicrobialsInfectious diseasesMedical servicesMethicillin-resistant staphylococcus aureusStaphylococcal infectionVancomycin Issue Published: 1 March 1991 PDF downloadLoading ...